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It is generally accepted that the main limiting step in the oxygenated metabolism o f . most PUFA is their liberation from membrane phospholipids I I , 21. This step, also called a deacylation process. may occur from several phospholipids in different ways, according t o the knowledge derived from the release of 2 0 : 4,ti -6 under specific agonist stimulation 12, 31 . The situation is not so clear in resting cells, although some PUFA must be released thereby allowing the acylation of others which act as markers of nutritional changes. It is admitted that the Lands pathway is the major one for remodelling PUFA containing phosphoglycerides 141. In resting cells, acyl-CoA synthetase and acyl-CoA : phospholipid acyltransferase activities occur together but a number of studies did not discriminate between them and have only reported the resulting acylation.
As compared with 2 0 : 4 , t i -6 , C,, PUFA (except 18: 2,ri -6 ) are poorly acylated into phospholipids. This has been investigated in platelets for the linolenic acid isomers, 1 8 : 3 , r i -6 and 18:3,rr-3 15. 61 , and stearidonic acid (I8:4.n--3) 151. It has been proposed that these PUFA would be elongated by platelets to their respective C2,, products which would be more readily acylated into phospholipids 151. This has been clearly observed in vivo with 18:3,n-6, of which the elongated product (20:3,1?-6) may accumulate t o a certain extent in platelet phospholipids [ 7, 81. However. it is well-known that membrane phospholipids are devoid of 20:3.n -3 and 20:4.n -3. the elongated products of IX:3,ri-3 and 18:4,ti-3, respectively 191. Although 1 8 : 2 , t i -6 is the best C,, substrate for the incorporation into platelet phospholipids, this is much less efficient than for C,,, PUFA, especially 20:4,n -6 for which a specific acyl-CoA synthetase might occur [ 101. The situation concerning the estcrification of lyso-platelet-activating factor, t o provide the platelet-activating factor (PAF ) precursor, might be substantially different where 20 Among C2,, PUFA, 20:4,ti -6 is usually the preferred substrate for the acylation process. However, 2 0 : 3 , n -6 o r 20:5,n -3 has been found to be as efficiently incorporated into platelets as 20:4, t i -6 16, lO[, depending o n the experimental conditions used. Accounting for the particular interest of the scientific community in 20: S , t i -3, a huge number of studies have been done with this PUFA [ 171. An important difference between 2 0 : S . n -3 and 20:4,ri -6 in platelets concerns their respective phospholipid distribution, the former being esterified in phosphatidylinositol in vivo at a very low level [ 18, 191, whereas it is substantially acylated into this glycerophospholipid in vitro 16 I. This discrepancy might well be explained by the active transfer of PUFA between phospholipid classes which has been clearly demonstrated for 20:4,ti -6 [20-221. In addition. it has been shown that platelet acyl-CoA :phospholipid acyltransferases specific for the synthesis o f phosphatidylinositol prefer ti -6 as opposed to ti -3 PUFA I 231. In contrast, the acylation of 20:S.n -3 into endothelial cell phospholipids does not seem to be specific for a special class [24] . In neutrophils, 20: 5 , r i -3 is incorporated mainly into phosphatidylcthanolamine and phosphatidylcholine, and particularly in the 1 -0 -alkyl subclass of the latter [2S] which is the PAF precursor. Since 1-O-alkyl-2-arachidonoylglycerophosphochoIinc is the preferred source for PAF generation [ 26, 27 I, the incorporation of 2 0 : 5 , t i -3 into this phospholipid might have specific biological effects in this respect.
Studies on C,: PUFA mainly concern adrenic ( 2 2 :4,ti -6 ) and cervonic ( 2 2 : 6 , n -3) acids. It is assumed that they are less efficiently acylated into platelet phospholipids 15. 6 I.
Phosphatidylethanolamine is the preferred target for 22:6.n-3 16, 281 and is its normal storaFe pool in many tissues [O]. In addition, this fatty acid is efficiently transferred from phosphatidylcholine t o phosphatidylethanol~imine under specific stimulation 1291. 22:4,n-6 and 2 2 : 6 . r i -3 are also taken up by cultured endothelial cells mainly into phosphatidylcholine and phosphatidylcthanolamine. where they may inhibit the oxygenated metabolism o f endogenous 20:4, n -6 , especially into prostacyclin 130, 31 I. In a longterm incubation, they tend t o be redistributed in the latter phospholipid at the expense of the former I 3 I ] . In neutrophils, 22:6,n -3 is incorporated into both phospholipids and triacylglycerols. The main phospholipid storage pools are again phosphatidylcholine and phosphatidylethanoIamine with a transient accumulation into phosphatidic acid
The deacylation process in blood and V~S C U~X cells appears relatively simple. as far as thc fatty acid specificity is concerned, but has only been investigated in response t o agonist stimulation. In platelets for instance, 2 0 : 4 , t i -6 is released from the phospholipid pool with a certain specificity, at least via phospholipase A,. This has been observed in various circumstances like intact cells I 331, plntelet mcmbranes [34] and purified phospholipase A, 135 I. However, close structurally related PUFA such as 2 0 : S , n -3 and 2 0 : 3 , r i -9 (having their first double bond at C-S) behave similarly to 20:4,11 -6 for this release reaction I 2Y, 341. The phospholipid substrate for such a phospholipasc A, activity is assumed to be both phosphatidylcholine and phosphatidylethanolamine, part of PUFA released from the former 1321.
phosphatidylcholine and reciprocally reacylated into I.'hosphatidylethanol~imine I2YI. Another possible source o f PU FA is phosphatidylinositol via the cascade phospholipasc C/diglyceride-monoglyceride lipases 136. 371. This possibility would not be relevant for PUFA different from 2 0 : 4,ti -6 , since the sri-2 position of phosphatidylinositol contains almost exclusively 20:4,ri -6. Very few studies have been done concerning the deacylation of PUFA in endothelial cells, except for 20:4.ri-6 which is assumed to he mainly released from phosphatidylcholine to be oxygenated into prostacyclin [38] . 20:5,ri-3 must also be released from the endothelium since PGI,. the prostacyclinlike molecule derived from 20: 5.11 -3, is produced after fish oil feeding 13c)]. Data from leucocytes arc also very scarce and wc may presume that the release of 20:4,t1-6 from the PA F precursor under agonist stimulation is highly specific. 
o .~~~c r l c i l i o r r
Once liberated fron the SII-2 position of phospholipids, each PUFA may be oxygenated specifically in the parent cell. and the oxygenated product may act in the same cell or another target cell, either as itself or after being structurally altered by the acceptor cell (41 I. Although all PUFA are not released from cell phospholipid storage pools, as mentioned above. we cannot exclude the possibility that these PUFA may undergo the oxygenation process when entering the cell from outside or after spontaneous release in the acylation/ deacylation cycle occurring in resting cells. The oxygenation by cell dioxygenases, essentially the cyclo-oxygenase and lipoxygenases. differs according t o the cell type and the structure of the PUFA.
C , x PUFA are weakly oxygenated. However. I 8 : 2 , t i -6 has been shown t o be substantially converted into 13-OH-9. I I -I 8 : 2. the end-product o f the 15-o r t i -6-lipoxygenase pathway. in cultured endothelial cells 1421. where it might play ;I role in inhibiting platelet adhesion 1431. More recently, the formation of Y-OH-lO.I2-18:2 from 18:2,ri-6 in the endothelium has also been reported 144). making the oxygenation o f 18:2.ti-6 in those cells similar to that previously described in leucocytes 1451. 18 : 3,ri -6 has also been reported t o be transformed into I 3-OH-6,0,1 1 -18 : 3 1461 via a putative platelet ti -6-lipoxygenase pathway 1471. In contrast. I 8 : 3 , t i -3 and I8:4.ti-3 are virtually not oxygeniited in platelets 120, 481, although the formation of small amounts of 1 2-OH-6,0. 13.1 5-18 : 4 could be observed from the latter. apparently via a dioxygenase-independent pathway C:,, PUFA are converted into various oxygenated metabolitcs through the dioxygenasc pathways. Apart from 20:4.ti-6, the large number o f metabolites of which allowed the establishment of the various oxygenation pathways. we may distinguish between the other prostanoid precursors (20:3,ti-6 and 20:5,1?-6) and the non-prostanoid precursors ( 2 0 : 3 , t i -3 and 20:4.11-3). From these latter, only 20:4.n -3 has been studied in platelets and reported t o be converted into I 2-OH- Finally, C22 PUFA havc been reported a s mainly oxygenated into monohydroxy derivatives via the diverse lipoxygenase pathways. In addition, ti -6 PUFA may also provide some dihomo-prostanoids but none is converted into leukotricnc-like molecules. Except for 22 :6,ti -3, which has been found to be converted into 7-0H-4,8,10,13,16,1 Y-22 : 6 via the 5-or t i -15-lipoxygenase pathway in leucocytes 1631, all the data available concern platelets and endothelial cells. Unexpectedly, 22 : 6 , t i -3 is oxygenated into two derivatives by platelet lipoxygenase, 14-0H-4,7,10,12,16,1Y-22:6, the normal t i -Y lipoxygenasc product, and I 1 -0 H -4,7,9,13,16,19-22:6, the former being predominant 1641. This peculiar metabolism seems t o be specific for C2? PUFA of the I I -3 family, since 22 : 5 , r i -3 is similarly oxygenated [CIS] . Incontrast,C,, PUFAisofthc ri-6family(22:4,ri-6 and 22 : S,ri -6 ) are transformed into only one derivative by platelet lipoxygenase (the 14-hydroxy derivative) but are also oxyFenated into dihomo analogues of thromboxane 166, 671. Similarly, 22 : 4,ri -6 is converted into dihomo-prostacyclin in cultured cndothclial cells 1301.
c 'otic~hrsior?
The main features of ti -3/11 -6 fatty acid metabolism in blood and vascular cells have been established. although several weaknesses remain concerning such a metabolism in certain cells like Icucocytcs, especially in discriminating between their different populations. However, much remains t o be determined about the metabolic conditions, their biological relevance and that of the metabolites formed, particularly with respect t o the nutritional conditions which provide the fatty acids. 
